生物制药公司Anavex Life Sciences Corp.（AVXL）今日盘中大跌5.02%，主要受到公司最新季度财报不及预期的影响。
根据公司公布的截至6月30日的季度业绩报告，Anavex调整后每股亏损16美分，低于分析师预期的14美分亏损。公司当季净亏损达1324万美元，收入为零，符合分析师预期。这一业绩表现不及市场预期，导致投资者信心受挫，引发股价下跌。
尽管短期内股价承压，但Anavex的长期表现仍然积极。数据显示，该公司股价在本季度上涨了23.1%，今年迄今为止上涨了5.7%。此外，华尔街分析师对Anavex保持乐观态度，目前对该公司股票的平均评级为"买入"，12个月目标价中位数为42.00美元，较最近收盘价11.35美元高出约73%。这表明分析师们仍看好公司的长期发展前景，尽管短期内可能面临挑战。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.